Clinical curative effect of nifedipine controlled-release tablets combined with telmisartan on diabetes mellitus combined with hypertension and their influences on serum homocysteine and C-reactive protein
10.3760/cma.j.cn115455-20200506-00562
- VernacularTitle:硝苯地平控释片联合替米沙坦治疗糖尿病合并高血压临床效果及对血清同型半胱氨酸、C-反应蛋白的影响
- Author:
Xiaolei LI
1
;
Xiaoling QI
;
Liwu XU
;
Wenwen HU
Author Information
1. 安徽省淮南市第一人民医院内分泌科 232001
- From:
Chinese Journal of Postgraduates of Medicine
2020;43(10):900-904
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the clinical curative effect of nifedipine controlled-release tablets combined with telmisartan on diabetes mellitus combined with hypertension and their influences on serum homocysteine (Hcy) and C-reactive protein (CRP).Methods:Eighty-four patients with diabetes mellitus and hypertension who were admitted to Huainan First People′s Hospital from February 2016 to November 2019 were enrolled. They were divided into combination group and control group by random number table method, with 42 cases in each group. The control group was treated with nifedipine controlled-release tablets, while combination group was additionally treated with telmisartan. Both groups were continuously treated for 4 weeks. After treatment, clinical curative effect in both groups was evaluated. The levels of diastolic blood pressure (DBP), systolic blood pressure (SBP), fasting plasma glucose (FPG), 2 h postprandial blood glucose (2 hPG), glycosylated hemoglobin (HbA 1c), total cholesterol (TC), triacylglycerol (TG), Hcy and CRP were measured before and after treatment. The number of cases with adverse reactions was recorded. Results:After treatment, total response rate in combination group was significantly higher than that in control group [92.24%(40/42) vs. 80.95%(34/42)] ( P<0.05). After treatment, there were no significant differences in FPG, 2 hPG and HbA 1c between the two groups ( P>0.05). After treatment, the levels of SBP, DBP, TC, TG, CRP and Hcy in combination group were significantly lower than those in control group [(132.64 ± 7.53) mmHg)(1 mmHg=0.133 kPa) vs. (142.81 ± 4.63) mmHg, (79.63 ± 6.84) mmHg vs.(85.71 ± 5.86) mmHg, (4.87 ± 0.61) mmol/L vs. (5.14 ± 0.62) mmol/L, (1.57 ± 0.41) mmol/L vs.(1.76 ± 0.45) mmol/L,(8.76 ± 1.53) mg/L vs. (9.51 ± 1.86) mg/L, (12.52 ± 1.97) μmol/L vs.(13.48 ± 2.36) μmol/L]( P<0.05). During treatment period, there was no significant difference in incidence of adverse reactions between combination group and control group [16.67% (7/42) vs. 19.05%(8/42)]( P>0.05). Conclusions:The clinical curative effect of nifedipine controlled-release tablets combined with telmisartan is good on diabetes mellitus combined with hypertension, which can regulate blood pressure, blood lipids, Hcy and CRP levels, and relieve disease progression, with good safety.
